Biotransformation within inflamed tissue of beta-endorphin 1-31 and three major N-terminal fragments; beta-endorphin 1-17, beta-endorphin 1-13, and beta-endorphin 1-11

Asvadi, Naghmeh Hajarol, Morgan, Michael, Hewavitharana, Amitha, Shaw, P. Nicholas and Cabot, Peter J. (2013). Biotransformation within inflamed tissue of beta-endorphin 1-31 and three major N-terminal fragments; beta-endorphin 1-17, beta-endorphin 1-13, and beta-endorphin 1-11. In: 40th International Symposium on High Performance Liquid Phase Separations and Related Techniques: Delegate Handbook. HPLC 2013: 40th International Symposium on High Performance Liquid Phase Separations and Related Techniques, Hobart, TAS, Australia, (115-115). 18-21 November, 2013.

Author Asvadi, Naghmeh Hajarol
Morgan, Michael
Hewavitharana, Amitha
Shaw, P. Nicholas
Cabot, Peter J.
Title of paper Biotransformation within inflamed tissue of beta-endorphin 1-31 and three major N-terminal fragments; beta-endorphin 1-17, beta-endorphin 1-13, and beta-endorphin 1-11
Conference name HPLC 2013: 40th International Symposium on High Performance Liquid Phase Separations and Related Techniques
Conference location Hobart, TAS, Australia
Conference dates 18-21 November, 2013
Proceedings title 40th International Symposium on High Performance Liquid Phase Separations and Related Techniques: Delegate Handbook
Publisher Royal Australian Chemical Institute (raci)
Publication Year 2013
Sub-type Published abstract
Open Access Status
Start page 115
End page 115
Total pages 1
Language eng
Formatted Abstract/Summary
Beta-endorphin 1-31 (BE) is an endogenous opioid peptide previously demonstrated to play roles in pain, reward, stress and the immune system. During inflammation, immune cell expression, production, and the release of BE increases within inflamed tissue. However, within the inflamed milieu BE is also susceptible to increased enzymatic degradation. BE and its three fragments were incubated in inflamed tissue homogenates at pH 5.5 for 2 hrs. The supernatants were separated using liquid chromatography/ mass spectrometry (LC/MS) on a C4 column followed by peak detection and identification using electrospray mass spectrometry on an API 3000 tandem mass spectrometer. BE 1-13 and BE 1-11 were identified as two of the major metabolites after incubation of BE 1-31 and BE 1-17 in inflamed tissue homogenates. BE 2-9, BE 2-13, and BE 2-17 were similarly the major metabolites after incubation of BE 1-17; BE 1-11 and BE 2-13 were detected in early fractions of BE 1-13 following incubation. The fragments, 2-11, 3-11, 4-11 and 2-9 were detected following incubation of BE 1-11. Potential hydrolysis sites of BE 1-31 were detected between the following amino acids: Lys9-Ser10, Pro13-Leu14, Leu17-Phe18, Phe18-Lys19, Lys19-Asn20. The primary site of hydrolysis in BE 1-17, 1-13, and BE 1-11 was shown to be between amino acids Tyr1-Gly2, providing analogues typically reported to be devoid of opioid activity.
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Conference Paper
Collection: School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Tue, 04 Mar 2014, 09:50:55 EST by Amitha Hewavitharana on behalf of School of Pharmacy